(June 21, 2024) – Moderna recently
announced the U.S. Food and Drug Administration has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.
--
Karen Braman